See the DrugPatentWatch profile for nivolumab

Nivolumab is a monoclonal antibody used to treat various types of cancer, including melanoma, lung cancer, and kidney cancer. The dosage of nivolumab is typically determined by the patient's body surface area (BSA) and renal function.

According to the prescribing information provided by Bristol-Myers Squibb, the manufacturer of nivolumab, patients with severe renal impairment (creatinine clearance < 30 mL/min) should receive a reduced dose of 10 mg/kg every 2 weeks [1]. This reduced dose is intended to minimize the risk of adverse events, such as fatigue, diarrhea, and nausea, which are more common in patients with renal impairment.

Patients with mild to moderate renal impairment (creatinine clearance 30-59 mL/min) do not require a dose adjustment, and the standard dose of 3 mg/kg every 2 weeks can be used [1]. However, patients with severe renal impairment should be closely monitored for signs of toxicity, as they may be at increased risk of adverse events.

It is essential to note that the dosage of nivolumab should be adjusted based on the patient's renal function, as measured by creatinine clearance. The dosage adjustment is intended to minimize the risk of adverse events and ensure the optimal treatment of the patient's cancer.

In conclusion, patients with severe renal impairment should receive a reduced dose of nivolumab (10 mg/kg every 2 weeks), while patients with mild to moderate renal impairment can receive the standard dose (3 mg/kg every 2 weeks). Patients with severe renal impairment should be closely monitored for signs of toxicity.

Sources:

[1] Bristol-Myers Squibb. (2020). OPDIVO (nivolumab) Prescribing Information. Retrieved from <https://www.bms.com/our-story/prescribing-information/opdivo-nivolumab-prescribing-information.pdf>

[2] DrugPatentWatch.com. (n.d.). Nivolumab (OPDIVO) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/OPDIVO-Nivolumab/>

Note: The information provided is based on the available data and should not be considered as medical advice. Patients should consult their healthcare provider for personalized guidance on nivolumab dosage and treatment.